Tryptamine Therapeutics Updates Director’s Securities Holdings

Story Highlights
Tryptamine Therapeutics Updates Director’s Securities Holdings

An update from Tryptamine Therapeutics ( (AU:TYP) ) is now available.

Tryptamine Therapeutics Limited has announced a change in the director’s interest in securities, specifically involving Chris Ntoumenopoulos. The changes include the acquisition of 8,750,000 ordinary fully paid shares and 4,375,000 options at $0.04 expiring on March 31, 2027. This adjustment in director’s holdings is part of a capital raising effort, reflecting strategic financial maneuvers to bolster the company’s market position.

More about Tryptamine Therapeutics

YTD Price Performance: -15.79%

Average Trading Volume: 1,658,752

Technical Sentiment Signal: Buy

Current Market Cap: A$40.85M

See more data about TYP stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App